VivoPower shares are trading higher after the company announced a distribution agreement with Sansure Biotech for the distribution of Mpox diagnostic tests in Singapore, Hong Kong, and Australia.
Portfolio Pulse from Benzinga Newsdesk
VivoPower shares rose following a distribution agreement with Sansure Biotech to distribute Mpox diagnostic tests in Singapore, Hong Kong, and Australia.
September 16, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
VivoPower's stock price increased due to a new distribution agreement with Sansure Biotech for Mpox diagnostic tests in key Asian markets.
The distribution agreement with Sansure Biotech is a positive development for VivoPower, as it expands their market reach in Asia for Mpox diagnostic tests. This news likely contributed to the rise in VivoPower's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100